RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug combo offers hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial is for people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) whose cancer came back or didn't respond to standard therapy. The study tests a chemotherapy drug combo called CPX-351 to find the safest dose and see if …
Matched conditions: RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
New drug combo aims to control rare, aggressive blood cancer
Disease control Recruiting nowThis study tests a combination of two drugs, enasidenib and azacitidine, in people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene mutation. The goal is to see if the treatment is safe and can shrink or control the cancer. About 63 participan…
Matched conditions: RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:43 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is either newly diagnosed or has returned/not responded to treatment. The goal is to see…
Matched conditions: RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:59 UTC